KTOV added another 600 shares here. Been doing some DD on this one and I am shocked its this low. They have a market cap of like 50 million or so here and looks like they have a drug that will probably get approval that could be worth 200 million a year easy. Their new drug addresses osteoarthritis and also lowers blood pressure. The current drug of choice to help relive the pain for this condition is over the counter pain relievers. But Over-the-counter pain relievers cause an increase in blood pressure which, in turn, can lead to cardiovascular disease. This drug looks like a big winner their stage 3 trials produced VERY!! good results. Late last year, Kitov scored big when its drug hit a primary efficacy endpoint in Phase III in a trial designed to measure drops in blood pressure in those receiving KIT-302. Kitov's drug lowered daytime systolic blood pressure by half as compared to patients receiving only Norvasc. Further data drilling showed KIT-302's beneficial effect on blood pressure was not limited to daytime systolic measures, but to nighttime as well, enhancing the drug's power. Celebrex alone was shown to increase blood pressure, as research predicted. End result - Kitov has created a new, safe way to take NSAIDs, revolutionizing the management of OA pain with one pill. I think this stock could very well get some attention from the big guys soon with this drug.
AI
Market Data 
Markets 
